Calliditas Therapeutics AB is a Stockholm, Sweden–based biopharmaceutical company focused on developing and commercializing specialty medicines for rare renal and autoimmune diseases. The company is best known for its work in IgA nephropathy (IgAN), where it has advanced a targeted, delayed-release budesonide therapy designed to act in the ileum to modulate the mucosal immune response associated with IgAN.
Calliditas markets its budesonide product for IgAN in select regions (including the United States) and collaborates with partners for commercialization in other markets. Beyond IgAN, its pipeline includes programs in fibrosis and inflammation, notably the NOX inhibitor setanaxib under evaluation across fibrotic and oncology-related indications. Calliditas is dual-listed on Nasdaq Stockholm (CALTX) and the Nasdaq Global Select Market in the U.S. (CALT).